Christopher S. Coffey
YOU?
Author Swipe
View article: Clinical and imaging characteristics of Parkinson’s disease with negative alpha-synuclein seed amplification assay
Clinical and imaging characteristics of Parkinson’s disease with negative alpha-synuclein seed amplification assay Open
Background The CSF alpha-synuclein (a-syn) seed amplification assay (CSFasynSAA) detects a-syn aggregation in over 90% of individuals with sporadic PD (sPD). However, the clinical characteristics of sPD with negative CSFasynSAA have not be…
View article: An updated, comprehensive meta-analysis of the treatment of anti-NMDAR encephalitis: Analysis, equipoise, and the urgent need for evidence over anecdote
An updated, comprehensive meta-analysis of the treatment of anti-NMDAR encephalitis: Analysis, equipoise, and the urgent need for evidence over anecdote Open
Since 2019, more patients have been treated early with first- and second-line immunotherapies. Functional outcomes have shown modest improvements, whereas mortality and relapse rates have remained unchanged.
View article: Neuronal α‐Synuclein Disease Stage Progression over 5 Years
Neuronal α‐Synuclein Disease Stage Progression over 5 Years Open
Background Neuronal α‐synuclein disease (NSD) is defined by the presence of an in vivo biomarker of neuronal alpha‐synuclein (n‐asyn) pathology. The NSD integrated staging system (NSD‐ISS) for research describes progression across the dise…
View article: An Updated, Comprehensive Meta-Analysis of the Treatment of Anti-Nmdar Encephalitis: Analysis, Equipoise, and the Urgent Need for Evidence Over Anecdote
An Updated, Comprehensive Meta-Analysis of the Treatment of Anti-Nmdar Encephalitis: Analysis, Equipoise, and the Urgent Need for Evidence Over Anecdote Open
View article: Neuronal alpha-Synuclein Disease stage progression over five years
Neuronal alpha-Synuclein Disease stage progression over five years Open
Background Neuronal alpha-Synuclein Disease (NSD) is defined by presence of an in vivo biomarker of neuronal alpha-synuclein (n-asyn) pathology, independent of presence of clinical syndrome. The NSD integrated staging system (NSD-ISS) desc…
View article: Smell testing to identify early alpha-synucleinopathy among people with dream enactment behavior
Smell testing to identify early alpha-synucleinopathy among people with dream enactment behavior Open
Background REM sleep behavior disorder (RBD) is an early manifestation of alpha-synucleinopathy in many cases. Dream enactment behavior (DEB), the clinical hallmark of RBD, has many etiologies and cannot be used alone to predict underlying…
View article: Eleven Years of Change: Disease Progression in Biomarker-Defined Sporadic Parkinson’s Disease
Eleven Years of Change: Disease Progression in Biomarker-Defined Sporadic Parkinson’s Disease Open
Long-term longitudinal data on outcomes in sporadic Parkinson’s Disease are limited, especially from cohorts with extensive biological characterization. Recent advances in biomarkers characterization of Parkinson’s Disease necessitate an u…
View article: A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease
A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease Open
Importance Identifying individuals in the earliest stages of synucleinopathy is essential to evaluate drugs aimed to slow progression or prevent manifest disease. Remote identification of hyposmic individuals may enable scalable recruitmen…
View article: Occupational Pesticide Exposure in Parkinson’s Disease Related to <i>GBA</i> and <i>LRRK2</i> Variants
Occupational Pesticide Exposure in Parkinson’s Disease Related to <i>GBA</i> and <i>LRRK2</i> Variants Open
Background: The penetrance of common genetic risk variants for Parkinson’s disease (PD) is low. Pesticide exposure increases PD risk, but how exposure affects penetrance is not well understood. Objective: To determine the relationship betw…
View article: A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research Open
View article: Neuronal Alpha-Synuclein Disease Stage Progression Over Five Years
Neuronal Alpha-Synuclein Disease Stage Progression Over Five Years Open
View article: Adult Moyamoya Disease and Syndrome: Current Perspectives and Future Directions: A Scientific Statement From the American Heart Association/American Stroke Association
Adult Moyamoya Disease and Syndrome: Current Perspectives and Future Directions: A Scientific Statement From the American Heart Association/American Stroke Association Open
Adult moyamoya disease and syndrome are rare disorders with significant morbidity and mortality. A writing group of experts was selected to conduct a literature search, summarize the current knowledge on the topic, and provide a road map f…
View article: A Biological Definition and Integrated Staging System of Neuronal alpha-Synuclein Disease
A Biological Definition and Integrated Staging System of Neuronal alpha-Synuclein Disease Open
<p>Abstract: Parkinson’s disease and dementia with Lewy Bodies share the same underlying<br>\nneurobiology (Lewy pathology with neuronal aggregates of pathologic alpha-synuclein)<br>\nyet are currently defined clini…
View article: Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression
Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression Open
Background: Identifying a meaningful progression metric for Parkinson’s disease (PD) that reflects heterogeneity remains a challenge. Objective: To assess the frequency and baseline predictors of progression to clinically relevant motor an…
View article: Predicting chronic postsurgical pain: current evidence and a novel program to develop predictive biomarker signatures
Predicting chronic postsurgical pain: current evidence and a novel program to develop predictive biomarker signatures Open
Chronic pain affects more than 50 million Americans. Treatments remain inadequate, in large part, because the pathophysiological mechanisms underlying the development of chronic pain remain poorly understood. Pain biomarkers could potentia…
View article: Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study Open
View article: Impact of the Dopamine System on Long‐Term Cognitive Impairment in Parkinson Disease: An Exploratory Study
Impact of the Dopamine System on Long‐Term Cognitive Impairment in Parkinson Disease: An Exploratory Study Open
Background Little is known about the impact of the dopamine system on development of cognitive impairment (CI) in Parkinson disease (PD). Objectives We used data from a multi‐site, international, prospective cohort study to explore the imp…
View article: Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay
Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay Open
Objectives Detection of α‐synuclein aggregates by seed amplification is a promising Parkinson disease biomarker assay. Understanding intraindividual relationships of α‐synuclein measures could inform optimal biomarker development. The obje…
View article: High Diagnostic Accuracy of the Α-Synuclein Seed Amplification Assay Informs Parkinson's Disease Heterogeneity and Disease Onset in the PPMI Cohort
High Diagnostic Accuracy of the Α-Synuclein Seed Amplification Assay Informs Parkinson's Disease Heterogeneity and Disease Onset in the PPMI Cohort Open
View article: The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis
The ExTINGUISH Trial: A Phase-2B Randomized Placebo-Controlled Trial of Inebilizumab in Anti-NMDA Receptor Encephalitis Open
Objective To assess the safety and efficacy of inebilizumab in patients with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. Background The lack of approved therapies for NMDAR encephalitis has led to substantial variability in tr…
View article: Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort Open
View article: Longitudinal Clinical and Biomarker Characteristics of Non-Manifesting <i>LRRK2<i> G2019S Carriers: The PPMI Cohort</i></i>
Longitudinal Clinical and Biomarker Characteristics of Non-Manifesting <i>LRRK2<i> G2019S Carriers: The PPMI Cohort</i></i> Open
View article: Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial
Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial Open
Background Glioblastoma (GBM) has a 5-year survival rate of 3%-5%. GBM treatment includes maximal resection followed by radiotherapy with concomitant and adjuvant temozolomide (TMZ). Cytochrome C oxidase (CcO) is a mitochondrial enzyme inv…
View article: High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease
High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease Open
View article: Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease
Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease Open
Background: Investigation of sex-related motor and non-motor differences and biological markers in Parkinson’s disease (PD) may improve precision medicine approach. Objective: To examine sex-related longitudinal changes in motor and non-mo…
View article: A cluster randomized trial to evaluate a centralized remote clinical pharmacy service in large, health system primary care clinics
A cluster randomized trial to evaluate a centralized remote clinical pharmacy service in large, health system primary care clinics Open
Background We developed a remote cardiovascular risk service (CVRS) managed by clinical pharmacists to support primary care teams. The purpose of this study was to examine whether the CVRS could improve guideline adherence in primary care …
View article: Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study
Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study Open
ManNAc showed long-term safety, biochemical efficacy consistent with the intended mechanism of action, and preliminary evidence clinical efficacy in patients with GNE myopathy.
View article: Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease Open
Background Cerebrospinal fluid (CSF) levels of monoamine metabolites may represent biomarkers of Parkinson's disease (PD). Objective The aim of this study was quantification of multiple metabolites in CSF from PD versus healthy control sub…
View article: Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis
Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis Open
Background: Sensitive and specific biomarkers for use in progressive multiple sclerosis (MS) have not been established. We investigate neurofilament light (NfL) as a treatment response biomarker in progressive MS. Objective: To evaluate wh…
View article: Dopamine transporter imaging predicts clinically‐defined <i>α</i>‐synucleinopathy in REM sleep behavior disorder
Dopamine transporter imaging predicts clinically‐defined <i>α</i>‐synucleinopathy in REM sleep behavior disorder Open
Introduction Individuals with idiopathic rapid eye movement sleep behavior disorder (iRBD) are at high risk for a clinical diagnosis of an α ‐synucleinopathy (aSN). They could serve as a key population for disease‐modifying trials. Abnorma…